Yahoo Web Search

Search results

  1. Jan 7, 2022 · NEW YORK, Jan. 7, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD ), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-derived therapies,...

  2. Jan 7, 2022 · NEW YORK, January 7, 2022 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-derived therapies, announces the resignation of Stephen Hurst from his role as a Director of the Company’s Board of Directors.

  3. en.wikipedia.org › wiki › MindMedMindMed - Wikipedia

    MindMed was founded in May 2019 by Jamon A. Rahn, an entrepreneur, Y-Combinator alumnus, and former Uber executive, and Stephen Hurst, a 35-year veteran of the pharmaceutical industry. Rahn, who was interested in the Silicon Valley trend of psychedelic microdosing to improve focus after struggling with his own mental health and addiction issues ...

  4. People also ask

  5. Jan 14, 2022 · MindMed Cofounder Stephen Hurst Resigns from Board. Shortly after we sent our bulletin last Friday, MindMed announced the resignation of co-founder and Board member (and, former co-CEO) Stephen Hurst. Hurst made a significant contribution to MindMed’s 18-MC program, which was acquired from Savant HWP, which Hurst co-founded and served as CEO.

  6. Stephen Hurst is the Board Director of MindMed, a psychedelic pharmaceutical company that he co-founded in May 2019 with JR Rahn. Hurst served as co-CEO of MindMed until he retired from the position in January 2021.

  7. Jan 7, 2022 · Jan. 7, 2022, 04:40 PM. NEW YORK, Jan. 7, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing...

  8. Jan 7, 2022 · --Mind Medicine Inc.,,, a leading biotech company developing psychedelic-derived therapies, announces the resignation of Stephen Hurst from his role as a Director of the Company's Board of Directors.

  1. People also search for